Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Launches Japan PIII Study for Foipan for COVID-19
November 10, 2020
- Big 4 Wholesalers Suffer 80% Drop in Operating Profit on COVID, Discount, Price Battle: 1H 2020
November 9, 2020
- Kyorin Jettisons Gene Therapy Ad-SGE-REIC after Bleak PII Results
November 9, 2020
- Expert Panel Delivers Harsh Verdict on Aducanumab, FDA Decision Due by March 7
November 9, 2020
- Xtandi Approved in China for Non-Metastatic CRPC
November 9, 2020
- Keytruda Top Selling Drug for 3 Months on End: Encise October Data
November 9, 2020
- 1st Half Sales of 7 Major Japan Drug Makers Skid 1.9% on Price Cuts, COVID-19; Core Products Brisk
November 6, 2020
- Before Aducanumab AdCom, Eisai CEO Voices Hopes for Potential 1st Alzheimer’s Drug in 17 Years
November 6, 2020
- Eisai Racks Up 5.9% Sales Increase in April-September on Lenvima Growth, Despite Price Cuts, COVID-19
November 6, 2020
- In a Digital Push, Takeda Encouraging Sales Reps to Gain IT Qualification: Japan Chief
November 5, 2020
- Mitsubishi Tanabe Incurs 60 Billion-Plus Yen Operating Loss in 1st Half as Parkinson’s Program Lags
November 5, 2020
- Prescriptions Down at 41% of Medical Institutions due to COVID-19: Survey
November 5, 2020
- AstraZeneca Approached Us for Manufacturing of Coronavirus Vaccine Solution: JCR Exec
November 5, 2020
- Sosei, Aditum Bio Form New Firm to Develop Neurological Disease Drugs
November 4, 2020
- Astellas Now Aims at Peak Sales of 300-400 Billion Yen for Padcev with New Indications
November 4, 2020
- Shionogi/Tetra’s Cognitive Disorder Med Delivers Positive PII Data
November 4, 2020
- JCR Can Strike Global Licensing Deal for Lysosomal Therapies at Least by March-End: Chief
November 4, 2020
- Kyowa Kirin’s Overseas Sales Ratio Nears 50%, Driven by Crysvita in Europe, US: January-September
November 4, 2020
- Daiichi Sankyo Promoting Home Use of Inavir to Reduce COVID-19 Risk at Medical Institutions
November 4, 2020
- Shionogi Drops March-End Goal to Start Clinical Trials for COVID-19 Treatment
November 2, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…